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Introduction
1INTRODUCTION
Polycystic kidney disease is characterized by development of
multiple cysts within the kidneys in bilateral fashion. A cyst is defined
as  a fluid filled sac lined with a single layer of fluid filled tubular
epithelium. Renal cysts may develop at any location along the renal
tubule from the glomerular capsule to the collecting duct by heritable,
developmental or acquired processes. Single or simple renal cysts are
acquired ,occur commonly in people older than 50 years of age, and are
not associated with any disease.
If cysts are solitary or infrequent, they must be distinguished from
haematoma or abscess, occasionally also from malignancy, particularly
lymphoma.
ADPKD is the most common mendelian disorder of the kidney
affecting all ethnic groups world wide with an incidence of
approximately 1 in 500-1000 births.
The heritable polycystic kidney diseases are autosomal dominant
and autosomal recessive disorders. The autosomal dominant disorders
include three systemic diseases:
2           1. Autosomal polycystic kidney disease
           2.Tuberous sclerosis complex
           3.Von hippel -lindau disease
The major recessive disorder is autosomal  recessive polycystic
kidney disease. Autosomal Dominant Polycystic Kidney Disease
(ADPKD) is the fourth common cause of chronic renal failure
throughout the world. It accounts for 8-10% of cases of End stage Renal
Disease(ESRD). ADPKD can manifest in fetuses, new borns or young
children and is the most common of the heritable polycystic kidney
disease1.
ADPKD is a systemic hereditary disorder transmitted in an
autosomal dominant manner with  virtually complete penetrance of the
abnormal genes. Positive family history  is present in 60% of patients.It
is also the most frequent life threatening hereditary disease affecting 1in
500 and 1 in 1,000 live births2. It occurs worldwide and in all races and
ethnic groups.
 ADPKD can occur  in fetuses, new borns, young children.
But ARPKD  remain undiagnosed  until  young  adulthood. It is often
evident on ultrasound  imaging in children, becomes symptomatic in
young adulthood ,progresses to end stage renal failure over a period of
3in  50-75%  of  affected  people.  By  contrast,  ARPKD  is  most  often
discovered in the first year of life and terminates in end stage renal
failure, in childhood or young adulthood .
Both kidneys are affected in bilateral and symmetrical fashion.
The kidneys are enlarged in size as the disease progresses. In  patients
less than 18-29 years old with a positive history of ADPKD, the
presence of two cysts, either unilateral or bilateral and  in patients 30-59
years  old  with  a  positive  history  of  ADPKD  atleast  two  cysts  in  each
kidney >60 years atleast four in each kidney is sufficient to make the
diagnosis.
In the absence of a family history of ADPKD, bilateral renal
enlargement  and  cysts  with  or  without  hepatic  cysts  and  absence  of
other manifestations suggesting a different renal cystic disease provide
presumptive evidence for the diagnosis. Contrast enhanced CT and MRI
provide better anatomic definition than ultrasound and are more helpful
to ascertain the severity and prognosis of the disease .
The major symptoms that cause those patients not detected by
family screening to seek medical attention are hypertension, flank pain,
urinary tract infection, hematuria, nephrolithiasis. Each of these
symptoms may manifest in 20-30% of patients.
4        Several risk factors for the progression of the functional renal
disease also have been identified including  gender, race, age, renal
volume, proteinuria, hematuria, hypertension, and LVMI. Among these
risk factors the most  readily treatable factor is the hypertension
associated with ADPKD. Hypertension is the most important symptom
present in 92% of patients at initial presentation .The hypertension in
ADPKD patients occurs at a mean age of 30 years  and is associated
with a substantial incidence of left ventricular hypertrophy (LVH). Since
cardiovascular events are the most common cause of death in ADPKD
patients, the occurrence of  hypertension and  LVH are  extremely
important cardiovascular risk factors for ADPKD patients. It has been
suggested that the presence of hypertension and the size of the cystic
kidneys are determinants of the progression of the renal functional loss.
Cardiovascular abnormalities are the important extrarenal manifestations
of ADPKD3. These patients have increased incidence of valvular
abnormalities such as mitral prolapse, aortic incompetence and tricuspid
prolapse. Aortic aneurysms may also occur with increased frequency in
ADPKD. Thus careful attention to the cardiac examination is warranted
in ADPKD patients and standard prophylaxis to prevent subacute
bacterial endocarditis should be carried out in family members with
valvular abnormalities.
5Hepatic cysts arise from dilatation of biliary microhamartomas
and from prebiliary glands. Other uncommon manifestations are
pancreatic, splenic, seminal vesical cysts and inguinal hernias. Bladder
cysts,arachnoid membrane cysts, spinal meningeal diverticula are
present in 10-40% of asymptomatic patients with ADPKD4.
The major concern in any young patient with ADPKD presenting
with a stroke is subarachnoid hemorrhage. An association between the
two conditions has been known for many years. Recent data from a
population  of  patients  with  ADPKD  suggest  that  12%  of  all  affected
patients died from a neurologic event, 6% of them from a subarachnoid
hemorrhage . Data on the prevalence of unruptured cerebral aneurysms
are more difficult to obtain, but will gradually improve as more
widespread screening is undertaken. In a large autopsy series,
unruptured intracranial aneurysms were identified in 4% of patients with
ADPKD who died from unrelated causes . Although this rate is higher
than that in the general population, the difference was not significant.
Asymptomatic intracranial aneurysms can be identified with either thin-
section CT scanning or magnetic resonance angiography (MRA).
Combined data from three large prospective studies suggest a
prevalence of approximately 8% in the ADPKD population; this figure
doubles in ADPKD patients who have a family history of intracranial
6aneurysm  .  Morbidity  and  mortality  after  rupture  of  an  aneurysm  are
high. In the autopsy series from the Mayo Clinic, mortality six months
after rupture was 55% , although in a more selected European
population, overall mortality was 10%, but 43% of those surviving
beyond three months after rupture had severe neurologic disability .
The most important determinant of whether an aneurysm will rupture
appears to be its size. In a series of otherwise normal patients with
unruptured cerebral aneurysms followed for eight years, all the ruptures
occurred when the aneurysm was greater than 10 mm in diameter .
Similar data are not yet available for a population of ADPKD patients,
but prospective studies are currently underway.
About 40% of affected members  initially deny a family history
but on careful examination  perhaps, only 10% lack an affected family
relative.  Inadequate  patient education still represent an impediment to
early disease detection, genetic counselling  and timely treatment of
disease complications.
 In view of diverse clinical presentations  and complications of
ADPKD, we conceptualized a study to analyse  extrarenal
manifestations of ADPKD in our indigenous population.
Aim of the Study
7AIMS AND OBJECTIVES
1.  To document various clinical presentations of ADPKD.
2.  To analyse various extrarenal manifestations of ADPKD
in our  native population
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Since autosomal dominant polycystic kidney disease (ADPKD) is
one of the most common genetic abnormalities seen in today’s medical
practice, many internists are likely to treat patients affected by this
condition.Genetic abnormalities have been increasingly recognized, and
the pathophysiology of the disease is beginning to be unravelled.
Because of advances in imaging technology, surrogate markers for
disease progression have allowed clinical studies of newer therapeutic
agents to proceed. In the near future, therapies for this common  genetic
disease may be available to either prevent or stabilize the disease course
for many affected individuals.
ADPKD is a systemic hereditary disorder transmitted in an
autosomal dominant manner. It is genetically heterogenous. The
systemic manifestations include cystic and non-cystic renal and
extrarenal abnormalities4,6,7.  Renal  cysts  occur  in  100%  of  gene
carriers1.
       Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the
fourth common cause of chronic renal failure throughout the world6.
Progressive expansion of multiple, bilateral renal cysts lead to massive
9enlargement of kidneys and to progressive renal failure. Although renal
cysts and renal failure are the cardinal manifestations of ADPKD, it is a
systemic disorder with multiple extrarenal manifestations encompassing
both cystic involvement of other organs and connective tissue
abnormalities. The observation that only one half of ADPKD population
reaches End stage renal disease(ESRD) by the middle of 6th decade8,9
and the dialysis survival for patients with ADPKD surpasses that of
general dialysis population10,11suggest that the extrarenal manifestations
of ADPKD have ample time to produce clinical complications.
GENETICS
During the past fifteen years an enormous amount of effort has
been invested in exploring the functions of the PC1 and PC2 proteins.
The return on this investment constitutes something of an
embarrassment of riches, in that the polycystin proteins appear to
participate in a nearly bewildering array of signaling pathways and
regulatory processes, and to reside within a complex collection of
subcellular structures.
A major goal of current ADPKD research is to elucidate the
connections between these cell biological properties of the polycystin
10
proteins and the pathogenesis of the disease that develops when their
expression is perturbed. One of the most intriguing discoveries to
emerge from this intense research is the realization that portions of the
cellular populations of PC1 and PC2 localize to the primary cilium.
ADPKD is the founding member of the “ciliopathies,” a recently
defined class of genetic disorders that result from mutations in genes
encoding cilia-associated proteins. These disorders are often
characterized by the presence of renal cysts as well as by additional
pathologies including neural tube defects, retinal malformations, and
polydactyly12. Although the cellular and molecular mechanisms
responsible for the pathogenesis of ADPKD are still very much the
subject of spirited and healthy debate, it has become clear in recent
years that understanding ADPKD, and the function or dysfunction of
PC1 and PC2, will require an appreciation of these proteins’ roles in the
primary cilium.
Recent advances in the molecular genetics of ADPKD include the
discovery of multiple genetic loci – PKD1 in chromosome 1613; PKD2
on chromosome 4 14,15  and  atleast one additional site unlinked to
chromosome 4 or chromosome 1616.
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ADPKD is thought to be an example of a “second hit”
phenomenon. An individual inherits a mutated polycystic kidney disease
gene from one of his or her parents. The wild-type or normal allele in
individual cells may then be affected by a so-called “second hit”
allowing this cell to proliferate and form individual cysts . No more than
5% of nephrons are thought to be involved in cystic change, but the
genetic mutation is obviously present in all cells. Some manifestations
of ADPKD, such as intracranial aneurysms, also persist in families.
PATHOPHYSIOLOGY AND PATHOBIOLOGY
Cystic kidneys usually maintain their reniform shape. Their size
ranges from minimally or moderately enlarged in early disease to more
than 20 times the normal size in advanced disease. Although unusual,
striking asymmetry of cyst development may be seen. Both the outer
and the cut surfaces show numerous cysts ranging in size from barely
visible to several centimeters in diameter. They are distributed evenly
throughout both the cortical and medullary parenchyma.
Polycystin 1 and 2, the gene products of PKD1 and PKD2  are
plasma membrane proteins that form components of a novel
multifunctional signaling pathway17.  These   polycystin  proteins  are
12
situated within the cell in areas involving the primary cilium. Thus,
mutated polycystins are an example of a ciliopathy. The cilia’s function
is to transmit mechanosensory signals into the cell controlling cell
growth and proliferation. Polycystin 1 is predicted to have a receptor
like structure and may be involved in cell-cell and/or cell-matrix
interaction. By contrast, polycystin 2 is thought to function as a subunit
of a non-selective cation channel. Both proteins have been to interact
invitro through their cytoplasmic region and transmit fluid-flow
mediated mechanosensation by the primary cilium in renal
epithelium17,18When the polycystins are mutated, a complex series of
events ensues. Disruption of the function of polycystin 1 or 2 may cause
ADPKD,  owing  to  the  inability  of  the  tubular  epithelial  cells  to  sense
mechanical cues that normally regulate tissue morphogenesis18 leading
to growth of individual cells and then to the formation of a fluid-filled
cyst . As the cyst gradually enlarges, it becomes pinched off from the
nephron of origin. Because fluid secretion continues, the result is a
gradually enlarging cystic kidney with an increased volume. The renal
parenchyma may also show abnormalities, but the primary
pathophysiologic process of the cystic kidney is a gradually enlarging
kidney with an increase in renal volume.
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         Although ADPKD is genetically dominant at the organismal level,
it is recessive at the cellular level. The kidneys of an ADPKD patient
who  inherits  one  mutated  copy  of  PC1  or  PC2  from  a  parent  will
develop and function normally into adulthood. Over time, however,
cysts will form in this patient’s kidneys and several studies suggest that
the cells that line these cysts will have lost both functional copies of a
polycystin gene. This indicates that an additional “second hit” somatic
mutation may cause cysts to form. According to this model, each cyst
arises as a consequence of a distinct somatic mutation event, explaining
the disease’s slow progression over the course of decades. Subtle factors
may also impact upon disease progression, including the level of PKD1
protein expression, the penetrance of pathogenic alleles, and the stage of
kidney development affected by PKD1 mutation .The slow
accumulation  of  cysts  throughout  adult  life  may  be  due  to  slow
accumulation of inactivating “second hit” mutations as a result of a
constant somatic mutation rate. It is also possible that, as individuals
age, their kidneys are more likely to suffer transient obstructive or
ischemic injuries to the tubule epithelial cells. These injuries would then
stimulate repair, which involves cellular growth and division. Given the
importance of PC1 and PC2 for cellular growth and differentiation, the
decreased levels of functional polycystin proteins present in the cells of
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individuals heterozygous for ADPKD mutation could perturb the repair
process and thus lead to cyst formation.
CYST EXPANSION
The macroscopic consequence of ADPKD progression is the
formation of fluid- filled cysts, which constitute a stark contrast to the
normally compact arrangement of tubules in a healthy kidney. At the
cellular level, this transformation is predicated upon two alterations:
cells must organize themselves to create spherical rather than tubular
structures, and the lumens of these structures must fill with fluid in order
to expand the consequent cysts.
The other critical aspect of cyst formation, which involves the
expansion of cyst fluid volume, can be understood as the conversion of
the cyst-lining cells from an ion-absorptive to an ionsecretory
epithelium. Ion secretion into the lumen then drives paracellular or
transcellular osmotic water movement into the cyst. A prime component
of  this  secretion  is  Cl-transport stimulated by cAMP. The fluid
movement driving cyst formation is stimulated by cAMP and involves
the apical cystic fibrosis transmembrane regulator (CFTR) and the
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basolateral Na+-K+-2Cl - cotransporter. PC1 may affect the expression,
localization, or activity of Cl- channels.
 Recent data have suggested that the progression of renal disease,
the occurrence of hypertension and symptoms of the disease are related
to kidney volume. In fact, in most cases, renal volume increases years
before the glomerular filtration rate starts to decrease, making the
glomerular filtration rate or its surrogate serum creatinine a poor way to
follow patients with ADPKD.
EFFECTS OF PC1 &PC2 THAT AFFECT MULTIPLE
SIGNALLING PATHWAYS
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Disease caused by PKD2 mutations is generally milder than
disease  caused  by  PKD1  mutations,with  an  older  age  at  diagnosis  and
later onset of hypertension and renal failure. In the reported ADPKD2
families to date onset of end stage renal failure occurred at a mean age
of 70-73 years,whereas in ADPKD1 families the mean age at onset of
ESRD is 53-56 years.
RENAL FUNCTION ABNORMALITIES
Impaired urinary concentrating capacity is common even at early
stages. Sixty percent of children cannot maximally concentrate the
urine. Plasma vasopressin levels are increased. The vasopressin-resistant
concentrating defect is not explained by reduced  cAMP or expression
of concentration associated genes, which are consistently increased in
animal models. Whether it is due to disruption of the medullary
architecture by the cysts or to a cellular defect directly linked to the
disruption of the polycycstin function has not been determined. Recent
studies suggest that the urinary concentrating defect and elevated
vasopressin levels may contribute to cystogenesis. They may also
contribute to the glomerular hyperfiltration seen in children and young
adults, and to the development of hypertension and chronic kidney
disease progression. Defective medullary trapping of ammonia and
17
transfer to the urine caused by the concentrating defect may contribute
to the low urine pH values, hypocitric aciduria, and predisposition to
stone formation.
Reduced renal blood flow is another early functional defect.It
may be due to the changes in intrarenal pressures, to neurohumoral or
local mediators, or to intrinsic vascular abnormalities. Mild to moderate
persistent proteinuria (150–1500 mg/day) may be found in a significant
number of patients in the middle to late stages of the disease. It is an
indicator of more progressive disease.
RENAL COMPLICATIONS
ADPKD patients may suffer complications such as infected cysts,
cyst rupture/hemorrhage, and nephrolithiasis that often cause crippling
acute renal pain.Pain is the most frequent symptom (?60%) reported by
adult patients. Some patients develop chronic flank pain without
identifiable etiology other than the cysts.
Acute pain may be due to
1. urinary tract infections
2.  renal  cyst infection/hemorrhage
3. nephrolithiasis
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URINARY TRACT INFECTIONS &CYST HEMORRHAGE
Subjects were considered as having UTI if there was a history of
two or more episodes of UTI. Patients were considered having gross
hematuria if there was a history of observing blood macroscopically in
the urine and microhematuria if the urinalysis showed up to 5 rbc/hpf.
Infected cysts can cause diffuse pain that may be unilateral or
bilateral, and the pain pattern can be similar to pyelonephritis in patients
with noncystic kidneys. UTIs in patients with ADPKD, however, can be
much more difficult to diagnose and manage than in patients with non-
cystic kidneys. UTIs occur in many patients with ADPKD and, as
expected, the incidence is much higher in women than in men. Most of
them were caused by enterobacteriaceae. In one report, 68% of women
with ADPKD had UTIs as compared with only 19% of men. Both
hematogenous spread and ascending infection are the presumed causes
for cyst involvement. A sudden increase in flank pain associated with
fever is the most common presentation of cyst infection. The pain
pattern tends to stay in one general area without radiation, not being
relieved by position change. Infected cysts may not be in
communication with the draining urinary tract in patients with ADPKD
19
and hence the urinalysis may be relatively benign and the urine cultures
can be persistently negative.
Management of upper tract infections in ADPKD may be
difficult, since antibiotics may not be able to cross the epithelial lining
of the cysts and produce a high enough concentration in the cyst fluid. It
is imperative that these UTIs be promptly treated to prevent ongoing
pain and other complications in these  non communicating infected cysts
such as sepsis, perinephric abscess, and subsequent renal failure.
Another common cause of acute flank pain in association with gross
hematuria in ADPKD is the rupture of cysts. Hemorrhage may be into a
communicating urinary tract. However, it is not certain that gross
hematuria represents hemorrhage into cysts communicating with the
urinary tract, since most cysts derived from proximal and distal tubule
segments grow as a result of aberrant tubulogenesis, and become walled
off  and  separate  from  the  tubules  of  origin  by  the  time  they  become
detectable by imaging studies. Gross hematuria is present in as many as
43% to greater than 50% of the patients with polycystic kidney disease.
Hemorrhage into a cyst occurs without gross hematuria when there is no
communication with the urinary tract. The frequency of hematuria from
cyst rupture correlates directly with the size of the kidneys, the
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incidence of hematuria increasing dramatically when one or both of the
kidneys is larger than 15 cm. Also, hypertensive ADPKD subjects are
more likely to have gross hematuria than normotensive patients.
Prognostic characteristics are noted with gross hematuria; the greater the
number of episodes, the worse the prognosis. Increased episodes of
gross hematuria are noted in association with a higher baseline serum
creatinine and episodes of bleeding before age 30 carry a worse renal
outcome.
In general, the episodes of hematuria are usually self-limited,
lasting two to seven days. These episodes tend to resolve spontaneously
with conservative management consisting of bedrest and hydration, but
persistent bleeding has been noted to occur for weeks. Pain related to
cyst rupture tends to be localized and definable by finger point.
However, referred pain to another location in the abdomen or up to the
shoulder (for example, with right kidney cyst rupture simulating biliary
colic) can occur with hemorrhage into a larger cyst, resulting in
compression of surrounding structures.
It is possible for significant bleeding into the renal cysts to occur
with subsequent formation of clots. This in turn may lead to urinary tract
obstruction and severe renal colic. Prolonged bed rest, intravenous
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hydration, heat and judicious narcotic administration are often necessary
in this circumstance.
It is also possible for cysts on the surface of the kidneys to rupture
and subsequent hemorrhage can result in a subcapsular hematoma. The
patient may then experience a mild steady flank pain until the hematoma
has been reabsorbed. Although nonsteroidal anti-inflammatory drugs
(NSAIDs) may be very helpful in the case of colicky pain, they must be
used cautiously and should not be the first line of treatment . Hematuria
may rarely be so severe and/or persistent as to necessitate transfusion.
In these cases, either nephrectomy or renal arterial embolization may be
necessary to control the bleeding. Embolization, although less invasive
than nephrectomy, can in itself cause severe continuous pain associated
with abdominal distension. This pain is due to renal parenchymal
ischemia in an enlarged kidney following embolization, and can be
difficult to control with conservative management and non-opioid
pharmacologic intervention.
Vascular endothelial growth factor (VEGF) produced by the
cystic epithelium  may promote  angiogenesis, hemorrhage into cysts,
and  gross hematuria. Symptomatic episodes likely underestimate the
frequency of cyst hemorrhage  because more than 90% of ADPKD
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patients have hyperdense (CT) or high-signal (MRI) cysts reflecting
blood or high protein content. Most hemorrhages resolve within 2 to 7
days. Nuclear imaging (67Ga or 111In-labelled  leukocyte scans) may be
helpful, but false-negative and false-positive results are  possible. Cyst
aspiration should be considered when the clinical setting and  imaging
are suggestive and blood and urine cultures are negative. It may follow
strenuous physical activity or minor trauma but often occurs
spontaneously. If hematuria is recurrent or persists for more than two
weeks and the patient has other risk factors associated with the
development of renal malignancies, then the possibility of neoplasm
should be investigated. Treatment of hematuria secondary to cyst
rupture consists of rest, hydration and analgesics.Renal cell carcinoma
(RCC) is a rare cause of pain in ADPKD.
NEPHROLITHIASIS
Patients with nephrolithiasis were defined as those with calculi
within the collecting system of the kidney on ultrasound with or without
a clinical history of stones. Criteria for the sonographic diagnosis of
calculus included identification of an echogenic focus with posterior
acoustic shadowing within the kidney but outside an identifiable cyst.
Calculi associated with cyst walls were not considered as calculi.
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Renal colic caused by kidney stones, another complication of
ADPKD,  occurs  in  about  20%  of  patients  with  ADPKD.  When
considering the spectrum of both symptomatic and asymptomatic stones,
about a third of the ADPKD patients have nephrolithiasis. This much
higher incidence of nephrolithiasis than in the general population is a
cause of significant morbidity in ADPKD patients because of flank pain,
hematuria and urinary tract infection. The prevalence of renal
calcifications, which represent stones within the collecting system,
interstitial calcifications, or calcifications within cysts, was found to be
50%  by  CT  in  a  study  by  Levine  and  Grantham.  While  patients  with
ADPKD develop a variety of kidney stones (calcium oxalate, calcium
phosphate, calcium carbonate, struvite), uric acid stones are more
common in polycystic kidney disease patients as compared to the
incidence in the general population, accounting for up to 50% of the
calculi formed.
            Mechanisms responsible for the increased association between
ADPKD and nephrolithiasis remain conjecture. Patients with ADPKD
may be predisposed to stone formation either because of a metabolic
defect(decreased ammonia excretion, low urinary PH  and low urinary
citrate concentration), structural abnormality secondary to cyst growth,
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renal tubular stasis, or a combination of these factors. It is noted that
approximately 50% of ADPKD patients have hypocitraturia. Renal
function of adult ADPKD patients with kidney stones is significantly
worse than in patients without stones. ADPKD stone formers have
larger predominant cyst size compared to non-stone formers. Increased
cyst number also is associated with stone formation. Therefore,
anatomic deformity related to cyst number, size, and growth may
contribute to the formation of kidney stones, possibly through a
mechanism of increased urinary stasis. Because of the compressed and
distorted renal calices, treatment modalities such as ureteroscopy,
extracorporeal shock wave lithotripsy (ESWL), and nephrolithotomy are
more difficult in patients with ADPKD. Since these therapeutic and
palliative procedures may not be as efficacious, ADPKD patients may
have to endure prolonged and repeated episodes of renal colic while
undergoing medical management addressed towards the etiology of the
stone formation. A rapidly progressive distension produced by stone
movement usually causes a much more severe pain than a slowly
increasing distension. Thus, it is critical that pain control be adequately
addressed while a detailed evaluation is underway. Renal prostaglandins
may be a major contributing factor in the symptom complex known as
renal colic. Acute ureteral obstruction by a stone can increase renal
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pressure, leading to a release of inflammatory mediating renal
prostaglandins. These prostaglandins, especially prostaglandin E2
(PGE2), cause vasodilation of the afferent arterioles in the kidney and
inhibition of antidiuretic hormone (ADH), with a resultant diuresis and a
further  increase  in  renal  pressure.  Thus,  a  vicious  cycle  may  be
established.
              A CT of the abdomen before and following contrast
enhancement is the best imaging technique to detect small uric acid
stones that may be very faint on plain films with tomograms and to
differentiate stones from cyst wall and parenchymal calcifications.
Stones may be missed if only a contrast-enhanced CT is obtained.
EXTRARENAL MANIFESTATIONS
CARDIOVASCULAR MANIFESTATIONS
The disease is characterized by renal and extrarenal involvement
with cystic and noncystic manifestations. With the availability of renal
replacement therapies for patients with end-stage renal disease (ESRD),
cardiovascular complications have emerged as a major cause of death in
patients with ADPKD.19 Hypertension is a common early finding and
can be the symptom that leads to the diagnosis of ADPKD.20
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Hypertension is also associated with a rapid progression to ESRD and
increased cardiovascular complications. Left ventricular hypertrophy
(LVH), which is an important risk factor for premature cardiovascular
death, occurs frequently in patients with ADPKD. Aneurysms and
cardiac valvular abnormalities are other cardiovascular manifestations of
this disease.
Hypertension is very common in ADPKD, and occurs in 50–70%
of patients before any substantial reduction in glomerular filtration rate
is observed.20Furthermore, hypertension occurs at a much earlier age in
patients with ADPKD than in the general population.21The median age
at diagnosis of hypertension in ADPKD was 32 years for males and 34
years for females,22 compared with a median age of 45–55 years in
patients with essential hypertension. Studies have reported that
hypertension occurs in 20–30% of children with ADPKD.23Moreover,
Schrier et al.23 demonstrated that the likelihood of hypertension in both
men and women with ADPKD was significantly greater when the
affected parent was hypertensive. Thus, the presence of hypertension in
the ADPKD-affected parent of a patient with ADPKD should alert the
clinician to the need for early detection and treatment of hypertension.
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Potential pathogenetic mechanism of
HT in ADPKD
Proliferation and expansion of cysts
Compression of renal blood vessels
Renin release
Angiotensin release
? Endothelial damage
due to oxidative
stress
? SNS activation
? Endothelin release
? TGF – ?? secretion
? Aldosterone release ? Angiogenesis? Growth factor
secretion
? Increased systemic
vascular resistance
? Sodium retention
and renal fibrosis
? Increased cyst
growth
Renal disease and Hypertension
SNS - Sympathetic Nervous System
TGF – Transforming growth factor
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ROLE OF THE RENIN-ANGIOTENSIN-ALDOSTERONE
SYSTEM
Renal structural changes have an important role in the
pathogenesis of hypertension in patients with ADPKD. Gabow et al.
reported that adult patients with ADPKD and hypertension had
significantly greater renal volume than patients with normal blood
pressure. These findings suggest that activation of the renin-angiotensin-
aldosterone system (RAAS) as a result of cyst expansion and local renal
ischemia has an important role in the development of hypertension in
this disease. Immunohistochemical studies of nephrectomy specimens
from patients with ADPKD have shown hyperplasia of renin-secreting
cells of the juxtaglomerular apparatus, which suggests chronic
stimulation of the RAAS is present. In addition, high levels of renin
were found in cyst fluid obtained from patients with ADPKD.
Loghman-Adham et al.  showed  that  other  components  of  the  RAAS,
including angiotensinogen, angiotensin-converting enzyme (ACE),
angiotensin II receptor and angiotensin II peptide were also present in
the cysts and dilated tubules of ADPKD kidneys. Activation of the
RAAS in ADPKD has been confirmed by the demonstration that plasma
renin activity and aldosterone concentrations in the supine and upright
positions, as well as after Captopril administration, are greater in
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patients with ADPKD, hypertension and normal renal function than in
patients with essential hypertension who are of the same age, sex, body
surface area, sodium excretion, renal function and mean arterial
pressure. Studies have also shown that administration of ACE inhibitors
decreases mean arterial pressure, renal vascular resistance and filtration
fraction significantly more in hypertensive patients with ADPKD than in
healthy controls with normal blood pressure. Total exchangeable
sodium, plasma renin activity and plasma aldosterone levels were
significantly higher in these patients than in family members of the same
age and sex. Similarly, reported that during chronically high sodium
intake, plasma renin activity was higher in patients with ADPKD who
had normal blood pressure and creatinine clearance greater than
70ml/min/1.73m2 than in unaffected controls from the same families.
These findings suggest that the RAAS is activated at an early stage of
ADPKD, and this activation precedes hypertension and the major
clinical manifestations of the disease.
Twenty-four-hour ambulatory blood pressure monitoring of
children or young adults without hypertension may reveal elevated
blood pressures, attenuated nocturnal blood pressure dipping, and
exaggerated blood pressure response during exercise, which may be
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accompanied by left ventricular hypertrophy and diastolic dysfunction.
Early detection and treatment of hypertension is important because
cardiovascular disease is the main cause of death
ROLE OF OTHER FACTORS
Although activation of the RAAS seems to have a major role in
the pathogenesis of hypertension in ADPKD, other factors might also be
involved. Harrap et al demonstrated that muscle sympathetic nerve
activity was increased in hypertensive patients with ADPKD regardless
of renal function, which suggests that sympathetic hyperactivity could
contribute to the pathogenesis of hypertension in this disease. Of note,
the RAAS is stimulated by increased sympathetic activity, and
angiotensin stimulates the sympathetic nervous system.
Plasma vasopressin levels correlate with blood pressure levels in
salt-sensitive forms of human and experimental hypertension. Since
plasma vasopressin concentrations are increased in patients with
ADPKD, vasopressin could also contribute to the development of
hypertension in this disease; however, this theory remains to be proven.
The cystic epithelium of kidney sections from patients with
ADPKD exhibits increased expression of endothelin 1. Endothelin 1 is
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also found in the cyst fluid. Patients with ADPKD have higher plasma
levels of endothelin 1 than do healthy controls and patients with
essential hypertension. Moreover, endothelium-dependent relaxation is
impaired and endothelial nitric oxide synthase activity is decreased in
patients with ADPKD. These findings suggest that endothelial
dysfunction secondary to impaired release of nitric oxide exists in these
patients. An imbalance in endothelium-derived vasoactive mediators
(that is, endothelin and nitric oxide) might, therefore, contribute to the
pathogenesis of hypertension in ADPKD. In a 2008 study,  Wang et
al.24investigated asymmetric dimethylarginine (ADMA) as a marker of
nitric oxide synthase inhibition and the lipid peroxidation product 13-
hydroxyoctadecadienoic acid as a marker of oxidative stress in patients
with early ADPKD. The investigators found that these patients had
significantly increased plasma ADMA and plasma 13-
hydroxyoctadecadienoic acid levels and significantly decreased urinary
clearance of ADMA compared with healthy controls. Demonstration of
endothelial dysfunction and increased carotid intima-media thickness in
both hypertensive and normotensive patients with ADPKD and well-
preserved renal function shows that atherosclerosis starts very early in
the course of this disease.25
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The findings of early-onset endothelial dysfunction mentioned
above were confirmed by a study that reported decreased coronary flow
velocity reserve—which represents the capacity of the coronary
circulation to dilate after an increase in myocardial oxygen demand—in
both hypertensive and normotensive patients with ADPKD. Furthermore
Borresen et al. investigated arterial stiffness in early ADPKD by pulse-
wave analysis and measurement of pulse-wave velocity. They found that
pulse-wave reflection was amplified even in young patients with
ADPKD who have normal blood pressure and renal function, which
demonstrates that pathological changes in the arterial system occur early
in the course of disease. The stimulation of angiotensin II and the
sympathetic nervous system  secondary to hyperinsulinemia might
contribute to increased LVMI in patients with PKD1.
ANEURYSMS
Patients with ADPKD have a greater prevalence of intracranial
aneurysms than the general population (4.0–11.7% versus 1.0%).
Ruptured intracranial aneurysms account for 4–7% of deaths in patients
with ADPKD and such deaths occur at a younger age than in the general
population. Aneurysmal involvement of extracranial arteries, such as the
coronary arteries, abdominal aorta, renal artery and splenic artery has
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also been reported in patients with ADPKD. Other reported vascular
manifestations of ADPKD are dolichoectasias (elongations and
distentions of the arteries caused by weakening of the vessel walls) and
dissections. Since polycystin 1 and polycystin 2 are both expressed in
vascular smooth muscle cells, interactions of these proteins with a single
pathway might have a role in the pathogenesis of aneurysms in ADPKD.
The early and effective treatment of hypertension is also
important for the prevention of cardiovascular complications in
ADPKD. Antihypertensive treatment with an ACE inhibitor reversed
LVH over a 7-year follow-up period, which decreased an important risk
factor for cardiovascular death in patients with ADPKD. A 7-year
prospective, randomized study in 75 hypertensive patients with ADPKD
and LVH compared the effects of rigorous and standard blood pressure
control (<120/80 mmHg versus 135–140/85–90 mmHg) on LVH and
renal function. Both strategies decreased LVH significantly; however,
rigorous blood pressure control was significantly more effective in
decreasing LVMI than was standard blood pressure control. In addition,
significantly more patients in the rigorous-control group (71%) than in
the standard-group (44%) achieved normal LVMI. A subgroup analysis
showed that patients who received the ACE inhibitor enalapril
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experienced a significantly greater decrease in LVH than patients who
received the calcium-channel blocker amlodipine, despite similar blood
pressure control. A blood pressure goal of less than 120/80 mmHg and
the use of an ACE inhibitor is, therefore, recommended for patients with
ADPKD who have hypertension and LVH.
HEPATIC CYSTS
    Hepatic cysts are the most common extrarenal manifestation of
ADPKD in 10 to 88% 26,27,28of patients. This high variability is probably
due to increasing prevalence of hepatic cysts with age. Cysts are
detectable in only 10-17% of patients below age of 40 years and 70-75%
of patients older than age of 60 years.26,29,30. Hepatic cysts are found in
60-75% of ADPKD patients with ESRD who are on or   approaching
dialysis 27,31.Hepatic cyst disease is most severe in patients with the most
severe renal cystic disease and the worst renal function 31; hepatic cysts
are found in 60% to 75%.
The prevalence of hepatic cysts in nonazotemic subjects is similar
for men and women; However severe hepatic cystic disease that is
increases  number  and  size  of  cysts,  primarily  affects  women,
particularly those who have had multiple prergnancies (or) exposure to
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exogenous female sex steroids27. By contrast to this female
predominance of severe hepatic cystic disease, females with ADPKD
are not at greater risk for severe renal cystic disease; in fact male
ADPKD patients have a faster rate of decline in Glomerular Filtration
Rate(GFR) than do females.
Isolated polycystic liver disease (that is, in the absence of renal
cysts) is a separate hereditary disorder that appears to be unrelated to
ADPKD. Genetic linkage studies document an absence of linkage to the
known ADPKD loci on chromosomes 4 and 16 .
Risk factors for the development of hepatic cysts in ADPKD are
1) Increasing age
2) Increasing severity of renal cystic disease
3) Decreased creatinine clearance
4) The number and size of hepatic cysts correlated with the
occurrence of pregnancy and number of pregnancies
5) Female gender
Liver function is well preserved and liver enzymes, bilirubin
usually remain normal in both male and female patients32,33. The
preservation of liver function in ADPKD patients with hepatic cysts was
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explained by a careful study done in women with massive hepatic cystic
disease that revealed preservation of a normal volume of hepatic
parenchyma despite a large number and volume of cysts
Complications of Hepatic cysts
 Fever, leucocytosis and right upper quadrant pain are the typical
symptoms of hepatic cyst infection. These symptoms could also arise
from infection of one or more renal cysts. It is usually monomicrobial
and caused by enterobacteriaceae.Hepatic cyst infections frequently
elevate AST, ALP or bilirubin. Since uncomplicated hepatic cysts
usually don’t elevate liver enzymes or biliubin enzymes, this finding can
help distinguish hepatic from renal cyst infection. Ultrasonogram seems
first choice among imaging technique to detect hepatic cyst.
If unsuccessful, Computed Tomography (CT) or Magnetic Resonance
Imaging (MRI) is indicated32.  MRI  sensitively  differentiates  between  a
complicated and an uncomplicated hepatic cyst. On CT scanning, fluid-
fluid levels within cysts, cyst wall thickening, intracystic gas bubbles,
and heterogeneous or increased density have been associated with
infection. Radionuclide imaging and more recently
18F-fluorodoxyglucose positron emission tomography scanning have
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been used for diagnosis..Infection usually affects patients with massive
hepatic cyst development31,32,38.
         Symptoms typically caused by massive enlargement of the liver or
by mass     effect from a single or a limited number of dominant cysts
include dyspnea, early satiety, gastroesophageal reflux, and mechanical
low back pain. Rare complications of massive ADPKD hepatic cystic
disease include obstructive jaundice35,36,37, portal hypertension with
oesophageal varices33,38and obstruction of hepatic venous outflow34,40.
These complications are thought to be due to compression of  biliary or
vascular structure respectively by a single dominant cyst or multiple
cysts.
A small number of patients, mostly women, develop disabling
abdominal pain and distention secondary to massive hepatomegaly from
large numbers and volume of hepatic cysts. Partial hepatectomy,
surgical fenestration, percutaneous drainage, or alcohol sclerosis of
several dominant cysts may be required to palliate such symptoms39
Congenital hepatic fibrosis, frequently associated with
Autosomal Recessive Polycystic Kidney. Disease also affects a small
number of families with typical ADPKD41.  Hepatic cysts in patients
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with ADPKD derive from intrahepatic biliary epithelium. Cysts grow as
a result of progressive dilation of biliary ductules in Von Meyenburg
complexes or biliary hamartomas, which e ventually separate from the
ductule of origin42,43.
CYSTS IN OTHER ORGANS
Cysts are found in pancreas in approximately 5%, arachnoid in
approximately 8%, and seminal vesicles in approxi-mately 40%.
Seminal vesicle cysts rarely result in infertility. Defective sperm motility
is another cause of male infertility in ADPKD. Pancreatic cysts are
almost always asymptomatic, with very rare occurrences of recurrent
pancreatitis. It is uncertain whether the reported association of
carcinoma of the pancreas represents more than chance. Arachnoid
membrane cysts are asymptomatic but may increase the risk for subdural
hematomas.  Spinal meningeal diverticula may occur with increased
frequency and rarely present with intracranial hypotension due to
cerebrospinal fluid leak. Ovarian cysts are not associated with ADPKD.
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INTRACRANIAL ANEURYSM
MRI BRAIN SHOWING ICA IN A PATIENT WITH ADPKD
NON ENHANCED CT BRAIN OF THE SAME PATINT
SHOWING SUBARACHNOID HEMORRHAGE
40
INTRACRANIAL ANEURYSM
            Rupture of an intracranial aneurysm (ICA) is one of the dreadest
complications of ADPKD. Autopsy series, case reports and prospective
imaging studies provide strong support for the relationship between ICA
and ADPKD44-48,  but  questions  remain  as  to  the  exact  prevalence  of
ICA,  the  identification  of  patients  at  high  risk  of  rupture,  and  whether
screening and prophylactic repair should be performed in asymptomatic
patients with small ICAs. The reported frequency of ICA ranges from
0% to 41% . The latter speculation is supported by the observation that
ICAs tend to cluster within families . Most ICAs occur in the anterior
circulation. Recent prospective imaging studies of asymptomatic
subjects using high-resolution computerized tomographic or magnetic
resonance imaging techniques with or without four-vessel cerebral
angiography found ICAs in 0% to 11% of subjects  all ICAs found in
these studies were less than 7 mm in size .45-48
Intracranial aneurysm produces symptoms via three mechanisms:
compression of adjacent structures, focal brain ischemia due to
embolism, and subarachnoid hemorrhage due to rupture. Urgent
neurologic or neurosurgical consultation should be obtained for ADPKD
patients with any new, severe, or focal neurologic symptoms, including
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headache. Rupture of an ICA is a catastrophic event, with mortality
approaching 50% and devastating morbidity affecting 50% of the
survivors. Kaehny and Everson suggested that patients with ADPKD
have a greater mortality rate from ICA rupture because of a greater
prevalence of renal insufficiency and hypertension than do patients
without
ADPKD however, when data derived from post-mortem studies
are excluded, the mortality rate is similar to that in the population
without ADPKD49 .  Intracranial  aneurysms  rupture  at  an  earlier  age  in
patients with ADPKD. Of reported ruptured ICAs in patients with
ADPKD, 64% to 80% occurred before age 50, whereas in patients
without ADPKD, rupture of ICAs occurred in only 40% to 45% before
age 50. Neurosurgical intervention for ruptured ICA is done primarily to
prevent recurrence of bleeding; few patients require evacuation of a
space-occupying hematoma to improve outcome. Rupture of an ICA is
only one of multiple diagnostic possibilities that must be considered
when evaluating an acute neurologic event in a patient with ADPKD.
Much more likely are cerebral complications due to hypertensive
cerebral hemorrhage or cerebral ischemia and infarction50,51 .  The
catastrophic outcome of ruptured ICA has prompted extensive
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discussion of the risks and benefits of screening and prophylactic repair
of ICA in asymptomatic patients with ADPKD. Levey et al formally
examined this question using decision analysis . Their analysis
suggested that screening and prophylactic repair only increased life
expectancy for patients younger than age 25.More recent data from large
prospective studies suggest that the prevalence of aneurysm in
asymptomatic patients with ADPKD is less than 10% .
The prevalence of asymptomatic ICA is 22% to 25% in family
members of ADPKD patients who are known to have ICA. More recent
estimates of surgical morbidity and mortality suggest a figure of 2% to
6%, rather than the 1% to 3% figure utilized in the initial analysis. These
datas strengthens the argument against angiographic screening for the
unselected ADPKD population. If, on the other hand, a highly sensitive
and specific noninvasive screening test (greater than 80% and 85%,
respectively) could define an individual ADPKD patient with a high
probability of having an ICA, angiographic study and prophylactic
repair of the lesion would confer a significant survival benefit . High
resolution three dimensional  magnetic resonance angiography (MRA)
with time-of-flight image processing techniques probably meets these
criterias and is the imaging modality of choice 52,53. It carries no risk of
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ionizing radiation, is noninvasive, and unlike computed tomography
(CT) angiography does not use iodinated contrast, which may be
nephrotoxic. If the population prevalence were 30% (that is, a positive
family  history  of  ICA),  the  positive  predictive  value  of  an  MRA
showing an ICA is 80%; therefore, in most patients with family histories
of ICA who have a positive MRA, angiography would reveal an ICA.
But patients with ADPKD appear to have an increased rate of
neurologic complications due to cerebral angiography, so it is highly
desirable to limit the number of studies . At present, no neurosurgical
consensus exists on the appropriate treatment for small, asymptomatic
KAs (less than 10 mm particularly for aneurysms larger than 5 mm .
Data derived from the general population indicate that the main
predictor of aneurysmal rupture is its size54,55. Wiebers and Torres
advocate repeated MRA screening of known asymptomatic, small ICAs
. They base their recommendation on data showing that there were no
ruptures of 102 ICAs less than 10 mm in diameter over a mean followup
period of eight years 56. Juvela et al advocate prophylactic repair of any
surgically accessible ICA, as long as the age and concurrent diseases of
that patient do not increase the surgical risk . Three studies clearly
document the formation and rupture of de-novo ICA in ADPKD patients
with prior ICA rupture 57-59. Data on long-term followup of known
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incidental (discovered solely via screening) ICA in patients with
ADPKD are very limited.  In a recent  study of 18 ADPKD patients,  15
asymptomatic, small (1.5—6.5 mm) ICAs were followed for a mean of
33 months using serial MRA examinations ; none of the aneurysms
changed in size or ruptured, and no de-novo aneurysms formed.
Autosomal-dominant polycystic kidney disease (ADPKD) patients with
either PKD1 or PKD2 mutations are at risk for intracranial aneurysms.
The efficacy of a screening program depends heavily upon the
sensitivity and specificity of the screening modality, the prevalence of
disease, and the potential benefit of a positive diagnosis.
DIAGNOSIS
The diagnosis of ADPKD in an individual with a positive family
history relies on imaging testing. Counseling should be done before
testing. Benefits of testing include certainty regarding diagnosis that
may influence family planning, early detection and treatment of disease
complications, and selection of genetically unaffected family members
for living related donor renal transplantation The sensitivity of
ultrasound to confirm a diagnosis of ADPKD in individuals who have a
50% a priori risk of having the disease by genetic linkage was studied
by Ravine et al. Currently used criteria of bilateral cysts with at least
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two in one kidney provides a sensitivity of 88.5% at age 15 to 29 years
and 100% at 30 years of age and above. Less stringent criteria in
subjects aged 15 to 29 years to establish a diagnosis of ADPKD for
individuals at risk would be at least two renal cysts (unilateral or
bilateral). More stringent criteria in those aged 30 to 59 years to
establish a diagnosis is the presence of at least two cysts in each kidney.
For at-risk individuals 60 years and older, at least four cysts in each
kidney should be required. Other reviews of ADPKD have established
less exact criteria to establish a diagnosis. By ultrasonography cysts are
round or oval, echolucent, thin?walled, clearly delineated structures with
smooth contours exhibiting sharply demarcated posterior walls and
sound wave amplification behind the cysts  as well  as  lateral  extinction
of the sound wave (lateral shadowing).
            These sonographic criteria are not applicable to more sensitive
imaging techniques such as computed tomography (CT) and magnetic
resonance imaging (MRI).There are two types of potential misdiagnosis.
In very young individuals, the diagnosis may be missed because the
renal parenchyma presents with a hyperdense texture only, but even at
this early stage hilar and intrarenal vessels exhibit unusually strong
vascular reflexes. Occasionally a CT scan permits detection of very
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small incipient cysts in such cases. While magnetic resonance imaging
(MRI) and computed tomography scanning are perhaps slightly more
sensitive for detecting cysts, the cost of these procedures is much greater
than ultrasonic examination and less widely available. At present,
ultrasound should be used preferentially for diagnosis.
At  present,  in  most  persons  with  a  50  percent  risk  of  autosomal
dominant polycystic kidney disease, imaging techniques are the only
mode of reaching a diagnosis before symptoms appear. In such persons
a negative ultrasonographic study during early adult life indicates that
the likelihood of inheriting a PKD1 mutation is small. In the few who
inherit a non-PKD1 mutation for polycystic kidney disease, renal failure
is likely to occur  relatively late in life.
With modern advances in genetics, the DNA sequence of
individual patients can be determined. However, these expensive tests
are not widely utilized at the present time, except in unusual cases to
confirm a questionable diagnosis or to exclude a possible organ donor in
a patient with a family history of ADPKD .
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MANAGEMENT
A patient with ADPKD managed by internists should have careful
blood pressure control and control of other cardiovascular risk factors
such as tobacco smoking, hyperlipidemia, body weight management,
and aggressive control of diabetes if present.
Pain in patients with polycystic kidney disease can be both acute
and chronic, often being difficult to manage in patients with more severe
symptoms.  However,  with the utilization of  a  variety of  traditional  and
recently available pain management techniques, pain can be managed
effectively in most of these patients. In addition, patients can be taught
"how to live with their pain" since permanent cure of chronic pain is
often not a realistic goal. Behavioral modification  approaches can help
patients adapt to chronic pain so as to not interfere with their lifestyle.
ADPKD patients may suffer complications such as infected cysts, cyst
rupture/hemorrhage, and nephrolithiasis that often cause crippling acute
renal pain.
The antibiotic therapy of UTI has been adapted according to urine
cultures and oral administration of antibiotics with good intracyst
penetration such as cotrimoxazole or preferably a fluoroquinolone such
as ciprofloxacin, had been choosen for long term prophylaxis. Highly
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ionized water-soluble drugs may have a low ability to penetrate this
barrier, whereas the use of nonionized lipid soluble antibiotics generally
can improve delivery into the cyst. Therefore, many antibiotics such as
the penicillins, cephalosporins, and aminoglycosides that have
traditionally been first line therapy for severe UTIs may not be effective
in ADPKD. Drugs with good cyst-penetrating ability, such as
clindamycin, trimethoprim-sulfamethozazole, metronidazole, and
fluoroquinolones may be more effective. However, it is possible that
even these may not be effective, necessitating surgical drainage of the
infected cysts.
The optimal treatment of patients with ADPKD should include a
blood pressure goal of 120/80 mmHg and the initiation of early RAAS
inhibition if microalbuminuria or LVH is present. Furthermore,
management of other cardiovascular risk factors, including smoking and
dyslipidemia, is extremely important. The diagnosis of hypertension in
ADPKD is often made late. Uncontrolled blood pressure increases the
morbidity and mortality from valvular heart disease and aneurysms, and
increases the risk of proteinuria, hematuria, and a faster decline of renal
function. The presence of hypertension also increases the risk of fetal
and maternal complications during pregnancy.
49
MANAGEMENT
APPROACH TO ASSESSMENT OF CARDIOVASCULAR RISK
FACTORS & MANAGEMENT IN PATIENTS WITH ADPKD
Diagnosis of ADPKD
Detection of blood pressure >130/80 mmHg
Measure urine
albumin
excretion
Assess
LVMI
Measure Plasma
LDL
Cholesterol
Assess
smoking
habit
If micro albuminuria (or)
LVH is present initiate anti
hypertensive treatment with
ACE inhibitor (Target BP
<120/80mmHg
Initiate statin
therapy if LDL
cholesterol
>3.37 mmol/L
Advise
smoking
cessation if
appropriate
LVMI- Left Ventricular Mass Index
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EMERGING TREATMENT STRATEGIES
Based on natural history studies involving MRI determinations of
annual increases in cyst volume, therapeutic trials of agents shown to
bebeneficial in animal models of cystic disease are anxiously awaited.
Clearly, no single unifying mechanism relates the normal
functions of the polycystin proteins to the pathology that develops in
their absence. It is, however, probably safe to assert that the progression
of cystic disease is predicated upon perturbations in two fundamental
processes. The epithelial cells that line cysts appear to proliferate
excessively and these cells secrete rather than absorb fluid and
electrolytes. . Thus, many current efforts aimed at developing small
molecule therapies for ADPKD target one or the other of these
derangements. Because fluid secretion into cyst lumens is mediated, at
least  in  part,  by  apical  CFTR  chloride  channels  and  is  stimulated  by
cAMP, both of these factors may constitute promising molecular targets.
The CFTR inhibitor compound CFTRinh172 appears to
substantially slow cyst expansion . Inhibition of a basolateral potassium
channel whose activity is required to maintain the electrochemical
potential that drives chloride and fluid secretion is also being explored
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as an approach to blocking cyst fluid accumulation. Antidiuretic
hormone (ADH), acting through the V2 vasopressin receptor, is a major
stimulant of cAMP production in the collecting tubule of the kidney.
Tolvaptan, a V2 receptor antagonist, dramatically reduces cyst
progression in mouse models of ADPKD. Ocreotide, a somatostatin
analogue, also inhibits cAMP accumulation in several cell types and has
produced intriguing results in animal models.
The observation that inappropriately high mTOR activity may
contribute to the excessive growth and proliferation that characterize
cystic tissue has prompted investigations into the utility of mTOR
inhibitors ,Sirolimus in the setting of ADPKD. Animal studies have
suggested dramatic beneficial effects, although recent clinical trial data
suggest that these results are not borne out in ADPKD patients, and the
side effects of chronic mTOR inhibition may be substantial enough to
further limit its potential utility.
Other efforts have directly targeted the regulation of mitosis.
Roscovitine, an anti-proliferative drug that blocks Cdks, dramatically
slows cyst formation in at least some animal models of PKD. Additional
emerging potential therapies are directed at other interesting targets.
These include triptolide, a compound derived from a traditional Chinese
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herbal therapy;  pioglitazone, a PPAR-alpha agonist; and Genz-123346,
which blocks glycosyl ceramide synthesis.  The connection between
these compounds’ molecular targets and the pathological processes
involved in ADPKD remain to be determined. Further exploring these
molecules, however, may reveal promising new pharmacological
approaches to treating this disease and may also shed light on as-yet-
undiscovered connections between the polycystin proteins and a variety
of cellular signaling and metabolic pathways.
Stabilization or a decrease in cyst volume will be the outcome
measure used to gauge therapeutic efficacy in these ongoing clinical
trials . If these therapies prove useful, screening of individuals at risk for
ADPKD will become more important because early initiation of such
therapy may prevent the progression to chronic kidney disease or even
end-stage renal failure.
Materials and
Methods
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MATERIALS  AND  METHODS
SETTING
 Patients attending the Department of Internal Medicine and
Department  of Nephrology, Madras medical college and Government
General hospital, Chennai.
COLLABORATION DEPARTMENTS
Institute of Internal Medicine
Department of Nephrology
ETHICAL APPROVAL
Institutional Ethical committee approved the study
STUDY DESIGN
Single center; Non randomized cross sectional study
DURATION
November 2009 - October 2010
SELECTION OF PATIENTS
Inclusion criteria
Both symptomatic and asymptomatic  patients with autosomal
dominant polycystic kidney disease  meeting imaging criteria.
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Exclusion criteria
1. Patients with simple cystic kidney disease
2. Patients not meeting  imaging criteria
SAMPLE SIZE
In  the  study  period  of  1  year  among  patients  seen  under  the
Department of Internal Medicine and Nephrology, after applying
inclusion criteria ,39 patients were included in this study.
CONSENT
All participants  gave informed consent.
METHODOLOGY
Patients who were included in this study were asked for the
history of abdominal &flank pain, abdominal distension, hematuria,
fever with rigors &chills, passage of stones, oliguria, bilateral leg
swelling, jaundice, chest pain, palpitation, breathlessness, headache,
giddiness ,stroke, family history, diabetes, hypertension, smoking,
alcohol consumption. The information was entered based on the
proforma prepared. Patients were subjected to Renal function tests,
Liver function tests, Urine culture, Electrocardiogram, Chest x-ray,
Echocardiogram, Ultrasonogram abdomen/ Computed tomography
abdomen and Magnetic resonance angiogram brain.
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STATISTICAL ANALYSIS
Excel worksheet / Fisher’s exact test
CONFLICT OF INTEREST
None
 Observations
and Results
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RESULTS
DEMOGRAPHIC ANALYSIS
AGE DISTRIBUTION
AGE FREQUENCY PERCENTAGE
31-40 8 20.5
41-50 16 41.0
51-60 12 30.8
61-70 3 7.7
SEX
SEX FREQUENCY PERCENTAGE
MALE 17 41.4
FEMALE 22 58.6
FAMILY HISTORY
FAMILY
HISTORY
FREQUENCY PERCENTAGE
P<0.001
SignificantPRESENT 24 61.5
ABSENT 15 38.4
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FLANK PAIN
FLANK PAIN FREQUENCY PERCENTAGE
P=0.0322
Significant
PRESENT 22 56.4
ABSENT 17 43.6
PALPABLE KIDNEY
PALPABLE
KIDNEY
FREQUENCY PERCENTAGE
P=0.1918
Not
significant
PRESENT 11 28.2
ABSENT 28 71.8
URINARY TRACT INFECTION
URINARY
TRACT
INFECTION
FREQUENCY PERCENTAGE P=0.001
Significant
PRESENT 23 65.5
ABSENT 16 34.5
60
61
RENAL CALCULI
RENAL
CALCULI
FREQUENCY PERCENTAGE
P=0.7734
Not
significant
PRESENT 15 38.5
ABSENT 24 61.5
CYST HEMORRHAGE
CYST
HEMORRHAGE
FREQUENCY PERCENTAGE
P=0.0145
SignificantPRESENT 9 23
ABSENT 30 77
HYPERTENSION
HYPERTENSION FREQUENCY PERCENTAGE
P=0.0001
Significant
PRESENT 29 74.3
ABSENT 10 25.6
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ECHOCARDIOGRAPHIC FINDINGS
ECHOCARDIOGRAPHIC
FINDINGS
FRE-
QUENCY
PERCENT-
AGE P=0.6132
Not
significant
PRESENT 5 12.8
ABSENT 34 87.2
LIVER CYST
LIVERCYST
FRE-
QUENCY
PERCENT-
AGE P=0.8040
Not
significant
PRESENT 6 15.4
ABSENT 33 84.6
PANCREATIC CYST
PANCREATIC
CYST
FREQUENCY PERCENTAGE
P=0.7278
Not
significant
PRESENT 2 5.1
ABSENT 37 94.9
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INGUINAL HERNIA
INGUINAL HERNIA FREQUENCY PERCENTAGE
PRESENT 2 6.9
ABSENT 37 94.9
INTRACRANIAL ANEURYSM
INTRACRANIAL
ANEURYSM
FREQUENCY PERCENTAGE
P=1.000
Not
significant
PRESENT 3 7.7
ABSENT 36 92.3
ENDSTAGE RENAL DISEASE (ESRD)
ESRD FREQUENCY PERCENTAGE
P=0.1445
Not
significant
PRESENT 25 64.1
ABSENT 14 35.9
Discussion
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DISCUSSION
AGE
Majority of patients in our study was in the age group of 41-50.
SEX
Females were predominantly affected than males.
FAMILY HISTORY
Family history of ADPKD was absent in 38.4% of patients in our
study which was statistically significant. However Lieske et al found
that 10% of patients had no family history of ADPKD. This significant
difference may be due to illiteracy and unawareness of the disease
among the patients in our study.
NEPHROLITHIASIS
Renal stones are a frequent complication of ADPKD and are
reported to occur in 11 to 34% of patients. Idrizia et al described
nephrolithiasis  in  42%   of  patients.  In  our  study,  renal  stones  were
present in 38.5% (n=15)of patients of which ten were female and five
were male patients.  However Torres et al found that incidence of
67
nephrolithiasis was equal between men and women in patients with
normal renal function.
FLANK PAIN, URINARY TRACT INFECTION(UTI), CYST
HAEMORRHAGE
Delaney et al studied 53 symptomatic adults for a mean followup
of   12  years,  of  which  flank  pain  was  present  in  30%  of  patients  and
symptomatic UTI  in 19% of patients. In our study, atleast one episode
of  UTI and flank pain  is present in 66.7% of patients.
Gabow et al described that gross hematuria was the presenting
symptom  in  15-20%  of  patients  and  occurs  atleast  once  in  30-50%  of
patients with ADPKD. Gross hematuria is usually secondary to renal
cyst rupture into the renal pelvis. Infection,segmental renal infection and
passage of renal calculi also cause gross hematuria in ADPKD. Isolated
cyst infections were detected by negative urine culture and absence of
white blood cell casts in urinary sediment. In our study cyst hemorrhage
was found in 23% of patients.
Milutinovic J et al studied clinical manifestations of 57 subjects
aged more than 50 years who had inherited ADPKD gene. Diagnosis
was made in 32/57 (56%)  of patients, clinical features were found in
31/57(55%), of which 47% had back pain and abdominal pain,
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symptoms consistent with UTI was present in 41% of patients,
hematuria and ESRD in 31% and 47% of patients respectively.
Statistically significant difference was not found in frequency of any of
the manifestation of ADPKD except UTI which was higher in women
(53%) than in men (27%).
PALPABLE KIDNEY
Delaney VB et al reported that palpable kidneys were found in
15% of 53 adult symptomatic ADPKD patients. In our study 28.2% of
patients had palpable kidney. This significant difference could be due to
smaller sample size in our study.
EXTRARENAL MANIFESTATION
CARDIOVASCULAR MANIFESTATIONS
Kenneth F, Hossack et al compared the prevalence of cardiac
abnormalities among 163 patients with ADPKD, 130 unaffected family
members and 100 control subjects in three groups. The prevalence of
Mitral valve prolapse was 26%, 14% and 2% respectively. He also
found a higher prevalence of mitral incompetence (31%,14%,9%
respectively), tricuspid incompetence (15%,7% and 4% respectively)
and tricuspid valve prolapse (6%, 2% and 0% respectively).
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Stephen B Humap et al found that echocardiography revealed no
difference in left ventricular mass index nor prevalence of mitral valve
prolapsed.
Ecder T,Schrier RW et al proposed that cardiovascular problems
are a major cause of morbidity and mortality in patients with ADPKD.
Hypertension is an early symptom of ADPKD and occurs in 60% of
patients before renal function has deteriorated. Hypertension is
associated with increased rate of  progression to ESRD and is the most
important potentially treatable variable in ADPKD. Left ventricular
hypertrophy(LVH) ,which is a powerful independent risk factor for
cardiovascular morbidity and mortality, also occurs frequently in
patients with ADPKD. Both hypertension and LVH have important role
in cardiovascular complications in these individuals. Morever
biventricular diastolic dysfunction, endothelial dysfunction, increased
carotid intima-media thickness and impaired coronary flow velocity
reserve are present even in young patients with ADPKD who have
normal blood pressure and well preserved renal function.
In our study we reported  29 out of 39 patients having hypertension
irrespective of  the presence of ESRD  which was stastically significant.
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Chapman  et  al  reported  that  48%  of  hypertensive  patients  with
ADPKD had Left ventricular Hypertrophy (LVH) and increased left
ventricular mass index (LVMI), which is associated with poor renal and
overall outcome.
In our study, out of  39 patients 5 patients (12.8%) had atleast one
valvular  manifestation. Irrespective  of valvular abnormalities 15  had
echocardiagraphic finding of LVH.
Leier et al reported that 18% of patients had one or more
cardiovascular abnormalities. Hossack KF et al have found that 26% ,
31% 8%,15%,6% of patients had mitral valve prolapse, mitral
incompetence, aortic incompetence, aortic incompetence, tricuspid
incompetence and tricuspid valve prolapse respectively. Timio M et al
reported that in a study of 228 patients of ADPKD over a 10 year
followup in a five generation kindred  25% had mitral valve prolapse,
30% had mitral incompetence, 5% had tricuspid valve prolapsed and
19% had aortic regurgitation. In our study out of 29 patients, 15 patients
had LVH irrespective of ESRD, 1 had tricuspid aortic valve, 2 had
mitral regurgitation,1 had mitral valve prolapsed and 1 had sigmoid
septum.
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LIVER CYSTS
Kumar VS et al reported that 18.5% of 92 ADPKD patients had
liver cysts. Liver cysts were more common in men and were mostly
multiple. In our study out of 39 patients 6 (15.4%)   had liver cyst.
PANCREATIC CYSTS
Torra et al had reported that approximately 9% of patients with
ADPKD had pancreatic cysts. Complications due to pancreatic cyst are
extremely rare but a case of chronic obstructive pancreatitis due to
pancreatic cyst has been reported by Malka D et al. Our study has
revealed that 5.1% of patients with ADPKD had pancreatic cyts of
which none of them developed complications.
INGUINAL HERNIA
Non cystic extrarenal manifestations like abdominal hernia is
usually prevalent in ADPKD. This is due to underlying defect in
extracellular matrix production with variable penetrance. In our study,
only 6.9% of patients presented with inguinal hernia.
INTRACRANIAL ANEURYSMS
P M Ruggieri et al done a study for occult  intracranial aneurysms
in polycystic kidney disease  by screening with MR angiography.
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Ninety-three patients with PCKD were screened for aneurysms with
spin-echo parenchymal magnetic resonance (MR) imaging and three-
dimensional time-of-flight MR angiography. Thirteen aneurysms, found
in 10 patients,  were 7 mm or smaller  in largest  dimension;  11 of  these
aneurysms were saccular. Conventional arteriograms, obtained in six
patients, helped confirm the MR angiographic findings. The best
estimates  of  prevalence  of  aneurysms  were  11.7%  in  the  study  group
(n = 93) and 25.8% in patients with a family history of aneurysms
(n = 6).
Arlene B .chapman et al  reported that four of  the 88 subjects  in
whom the radiologic studies were successfully completed had
intracranial aneurysms (4 percent; 95 percent confidence interval, 0.1 to
9 percent), as compared with the prevalence of 1 percent reported for an
angiographic study of the general population. In our study we reported
ICAs in 3 out of 39 patients contributing to 7.7%.out of these one
patient was symptomatic and presented as subarachnoid hemorrhage
even  before  the  diagnosis  of  ADPKD.  Lozano   AM  et  al  reported
aneurysmal rupture at a younger age in patients with ADPKD (mean age
around 40%) .
Conclusion
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CONCLUSION
1)  Urinary tract infection, especially in females, is the most common
clinical manifestation in ADPKD. Most common organism was
found to be enterobacteriaceae.
2)  Liver cysts are the most common extrarenal manifestation in
ADPKD.
3)  Renal ultrasound screening of  young hypertensive individuals
should be considered  when searching for causes of secondary
hypertension.
4)  In evaluating every case  of SAH ,normo or hypertensive ,it is
mandatory to rule out ADPKD.
5)   Hypertension can manifest in patients with ADPKD even before
the onset of  end stage renal disease.
6) Multisystem involvement  in ADPKD reflects the systemic nature
of polycystic kidney disease and supports the hypothesis that the
disorder involves a defect in ECM(Extracellular matrix) and the
various manifestations are an expression of that defect.
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Study Proforma
STUDY  PROFORMA
Name                               :
Age/Sex                           :
Address                           :
Annual Income               :
Socio economic class      :
MRD No                          :
Study id no                      :
CLINICAL DATA
HISTORY:
Presenting complaints:
  Flank pain, hematuria, abdominal distension, giddiness,
headache, jaundice, Palpitations, chest pain, dyspnoea,
fever,syncope,seizures,pedal edema
Past History:
Diabetes mellitus, systemic hypertension, liver disease,
cardiac disease.
Treatment history: ( including any surgeries)
Personal history:
Smoking,  alcohol, menstrual complaints for female
patients.
Family history:
Seizures,CVA
PHYSICAL EXAMINATION:
General examination:
General well being, dyspnoea, pallor, jaundice, pedal
edema.
Vital signs:
Pulse rate:                                                                   BP:
Respiratory rate:                                                        Temp:
JVP:
Systemic examination:
CVS:
RS:
ABDOMEN:
{masses, hepatosplenomegaly, ascites }
LABORATORY DATA
PRELIMINARY INVESTIGATIONS:
TEST RESULT
Fasting blood sugar
Blood urea, serum creatinine
CBC
Serum bilirubin
Direct/ indirect bilirubin
AST/ALT
SAP
Total protein
Serum albumin/ globulin
Urine routine
CXR PA View
ECG
ECHO
USG Abdomen/ CT
SPECIAL INVESTIGATIONS:
MR Angiography:
INFERENCE:
Abbreviations
ABBREVIATIONS
ADPKD   -    Autosomal Dominant Polycystic Kidney Disease
LVMI       -    Left ventricular Mass Index
PC1 - Polycystin 1
PC2 - Polycystin 2
UIA           -   Unruptured  Intracranial aneurysm
RAAS        -   Renin Angiotensin Aldosterone System
LVH          -    Left ventricular hypertrophy
ESRD        -    End Stage Renal Disease
GFR - Glomerular  Filteration  Rate
m TOR - Mammalian Target of  Rapamycin
cdk - Cyclin Dependent Kinases
TSC -  Tuberous Sclerosis Complex
Master Chart
Sl.No. Name Age Sex Family h/o HT Echo Liver cyst Panc cyst Ing hernia ICA Flank pain Pal kidney UTI Calculi Cyst hge ESRD
1 Sahadev 35 MALE NO YES LVH NO NO NO NO NO YES NO NO NO YES
2 Kalathee 46 MALE NO YES LVH,TAV YES NO YES YES YES YES YES YES YES YES
3 Natarajan 45 MALE YES YES NORMAL NO YES NO NO YES NO YES NO NO YES
4 Devendran 35 MALE YES YES LVH NO NO NO NO NO NO NO NO NO NO
5 Loganath 44 MALE NO YES NORMAL NO NO NO NO YES YES YES YES NO YES
6 Muthulax 43 FEMALE NO YES NORMAL NO NO NO NO NO NO YES NO NO YES
7 Lakshmi 45 FEMALE YES YES LVH YES NO NO NO YES NO YES NO NO YES
8 Rahman 54 MALE NO YES MR NO NO NO NO YES YES YES NO NO YES
9 Lakshmi 55 FEMALE YES YES NORMAL NO NO NO NO NO NO NO NO NO YES
10 Ramakrish 55 MALE YES YES sigmoidseptum  NO NO NO NO YES YES YES NO NO YES
11 Packiriam 53 FEMALE YES NO NORMAL NO NO NO YES NO YES NO NO NO NO
12 Thiruppal 40 FEMALE YES YES LVH YES NO NO NO YES YES YES YES NO YES
13 Anbazhag 50 MALE NO NO LVH NO NO NO NO YES YES YES YES NO YES
14 Renuka 47 FEMALE YES yes NORMAL YES NO NO NO YES YES NO NO NO NO
15 Dhanam 48 FEMALE NO YES NORMAL YES NO NO NO YES NO YES NO NO YES
16 Pattammal 60 FEMALE NO NO NORMAL NO NO NO NO YES NO YES NO NO NO
17 Tamilarasi 43 FEMALE YES NO NORMAL NO NO NO NO NO NO NO YES YES NO
18 Kuttyamma 46 FEMALE YES YES LVH NO NO NO NO YES NO YES YES NO YES
19 Balakrishnan 59 MALE YES YES LVH NO NO NO NO NO NO NO NO YES YES
20 Palanisamy 58 MALE NO NO NORMAL NO NO NO NO NO NO YES NO YES NO
21 Mani 37 MALE YES NO NORMAL NO NO NO NO NO NO NO NO YES NO
22 Raman 49 MALE NO YES LVH NO NO NO NO YES YES NO NO NO YES
23 Shanmugham 66 MALE YES YES MVP NO NO NO NO NO NO YES NO NO YES
24 Sulochana 36 FEMALE YES YES LVH NO NO NO NO NO NO YES YES NO YES
25 Rohini 51 FEMALE YES NO NORMAL NO NO NO NO YES NO NO YES NO NO
26 Kumariamma 64 FEMALE YES YES NORMAL no NO NO NO NO NO NO YES YES NO
27 Renuka 31 FEMALE YES YES LVH NO NO NO NO YES NO YES NO NO NO
28 Devasaga 50 MALE YES YES LVH NO NO NO NO YES YES YES YES NO YES
29 Abraham 45 MALE YES NO NORMAL NO NO NO NO NO NO NO NO NO NO
30 Pushpa 70 FEMALE YES YES LVH NO NO NO NO NO NO YES YES NO YES
31 Maryamma 60 FEMALE NO YES LVH NO NO NO NO YES NO YES NO NO YES
32 Kannamm 43 FEMALE YES YES NORMAL NO NO NO YES NO NO YES NO NO YES
33 Thangadu 37 MALE YES NO NORMAL NO NO YES NO YES NO NO NO NO NO
34 Fathima 42 FEMALE NO YES NORMAL n0 NO NO NO YES NO YES NO NO YES
35 Kullammal 53 FEMALE YES YES MR YES NO NO NO NO NO YES YES NO YES
36 Raju 39 MALE NO YES NORMAL NO NO NO NO YES NO YES YES YES NO
37 Mohana 56 FEMALE NO YES NORMAL NO NO NO NO YES NO NO YES YES YES
38 Velamma 44 FEMALE NO YES NORMAL NO NO NO NO NO NO NO NO YES NO
39 Chinnaponn 54 FEMALE YES YES LVH NO NO NO NO YES NO NO YES NO YES
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